IMMUNITYBIO, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
IMMUNITYBIO, INC. (IBRX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.72 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-04
- IMMUNITYBIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $1.72M.
- IMMUNITYBIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $1.38M.
- IMMUNITYBIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $5.90M, a 129.15% increase from fiscal 2024.
- IMMUNITYBIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $2.58M.
- IMMUNITYBIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- IMMUNITYBIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $14.80M, a 35.85% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.72M 10-Q · filed 2026-08-04 | $3.10M derived: sum of 3 quarters · filed 2026-08-04 | $3.10M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $1.72M 10-Q · filed 2026-05-07 | $3.10M derived: sum of 2 quarters · filed 2026-05-07 | $3.10M derived: sum of 3 quarters · filed 2026-05-07 | $7.62M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.38M derived: sum of 2 quarters · filed 2026-02-23 | $5.90M derived: sum of 3 quarters · filed 2026-08-04 | $5.90M 10-K · filed 2026-02-23 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.53M derived: sum of 2 quarters · filed 2026-08-04 | $4.53M 10-Q · filed 2025-11-05 | $4.53M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-06-30 | $4.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $4.53M 10-Q · filed 2026-08-04 | $4.53M derived: sum of 3 quarters · filed 2026-08-04 | $7.10M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $2.58M derived: sum of 3 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $2.58M derived: sum of 2 quarters · filed 2026-02-23 | $2.58M 10-K · filed 2026-02-23 | |||
| 2024-09-30 | $2.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.58M 10-Q · filed 2025-11-05 | ||||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-05 | |||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $1.01M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $1.01M derived: sum of 3 quarters · filed 2025-03-03 | $812.00K derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | $1.01M derived: sum of 2 quarters · filed 2025-03-03 | $812.00K derived: sum of 3 quarters · filed 2025-03-03 | $13.89M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $812.00K derived: sum of 2 quarters · filed 2025-03-03 | $13.89M derived: sum of 3 quarters · filed 2025-03-03 | $14.80M 10-K · filed 2025-03-03 | ||
| 2022-09-30 | -$199.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $12.88M derived: sum of 2 quarters · filed 2023-11-09 | $13.79M 10-Q · filed 2023-11-09 | $17.39M derived: sum of 4 quarters · filed 2024-03-19 | ||
| 2022-06-30 | $13.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $13.99M 10-Q · filed 2023-08-08 | $17.59M derived: sum of 3 quarters · filed 2024-03-19 | $24.69M derived: sum of 4 quarters · filed 2024-03-19 | ||
| 2022-03-31 | $911.00K 10-Q · filed 2023-05-11 | $4.52M derived: sum of 2 quarters · filed 2024-03-19 | $11.62M derived: sum of 3 quarters · filed 2024-03-19 | $22.59M derived: sum of 4 quarters · filed 2024-03-19 | ||
| 2021-12-31 | $3.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $10.71M derived: sum of 2 quarters · filed 2024-03-19 | $21.68M derived: sum of 3 quarters · filed 2024-03-19 | $23.07M 10-K · filed 2024-03-19 | ||
| 2021-09-30 | $7.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $18.07M derived: sum of 2 quarters · filed 2022-11-09 | $19.46M 10-Q · filed 2022-11-09 | $20.36M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | $10.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $12.36M 10-Q · filed 2022-08-08 | $13.26M derived: sum of 3 quarters · filed 2023-03-01 | $14.76M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $1.39M 10-Q · filed 2022-05-10 | $2.29M derived: sum of 2 quarters · filed 2023-03-01 | $3.78M derived: sum of 3 quarters · filed 2023-03-01 | $3.78M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $902.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $2.39M derived: sum of 2 quarters · filed 2023-03-01 | $2.39M derived: sum of 3 quarters · filed 2023-03-01 | $2.39M 10-K · filed 2023-03-01 | $5.16M 10-K · filed 2021-03-04 | |
| 2020-09-30 | $1.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $1.49M derived: sum of 2 quarters · filed 2021-11-12 | $1.49M 10-Q · filed 2021-11-12 | $5.16M 10-Q · filed 2020-11-09 | $2.66M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | $1.17M derived: sum of 3 quarters · filed 2022-03-01 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-14 | $1.17M derived: sum of 2 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.97M 10-K · filed 2022-03-01 | $800.00K 10-K · filed 2020-03-25 | |||
| 2019-09-30 | $800.00K 10-Q · filed 2020-11-09 | |||||
| 2018-12-31 | $0.00 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |